Reuters - Takeda Pharmaceutical Co Ltd (4502.T) said on Thursday that the U.S. Food and Drug Administration has extended its review of Takeda’s fixed-dose diabetes drug combing alogliptin and Actos to Sept. 4. The FDA had asked Takeda to conduct an additional cardiovascular safety trial for alogliptin in June.
